View study details on clinicaltrials.gov.
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Location: CPMC (San Francisco)
Please contact: ClinicalResearch@sutterhealth.org about study TRAILBLAZER-ALZ 3
Stupski Serious Illness Program Evaluation
Investigator: Sylvia Sudat, PhD